amgen's additional $3 billion a year..., page-22

First off, it's important to clarify a clear distinction between Prana (PBT) and Patrys (PAB).



Prana: Theoretical chemical reduction of unwanted protein build up. The chemical is an analogue (highly similar to) dyes, resins, etc... not something I'll let willingly put in a person without damn good cause (and data, with p values). But still, it MAY work, and if it does...fantastic. My advice, IF HOLDING - DON'T SELL. There may be a dead cat bounce to come...may.



Patrys: a proven natural human immune response to unwanted cells. Natural Human Antibodies are tried and tested, it's where the industry started in the first place. But now, with advancements in the production of the antibody class Immunoglobulin M (IgM) it's financially possible to produce mass quantities competitively. Safe, proven, natural. Leveraging recent developments in production technology (for example the PER.C6 cell line) is producing dramatic cost savings in the economies of scale. Patry's is boasting 1<2grams/litre, which for a IgM is very, very good. Safe, targeted, works on it's own, and is even better in a combo...Amgen wants that combo.



The relevant clinical trial, which was modestly stated by the CEO Dr. Roskrow as "favourably comparative", to Patrys's product reveals some striking differences. It's very interesting that Dr. Roskrow would drop this comparative bread crumb...


As stated before,

Elotuzumab later resulted in a $30M upfront payment, and up to $680M in royalties depending on milestones.


Patrys's currently sitting on a $30M market cap, with $10M cash in bank.




The differences in study design, IMHO, show a more controlled and considered approach for Patrys than Elotuzumab. Smaller study (lower costs), smaller dosing (lower costs, lower risk) yet Patrys achieved superior biological results... a fantastic and promising result.